Anissa Abi-Dargham

Anissa Abi-Dargham's AcademicInfluence.com Rankings

Anissa Abi-Dargham

Biology

#8358

World Rank

#11421

Historical Rank

#2325

USA Rank

biology Degrees

Download Badge

Biology

Why Is Anissa Abi-Dargham Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Anissa Abi-Dargham is an American psychiatrist and researcher. She is a psychiatry professor and vice-chair of research at Stony Brook University and professor emerita at the Columbia University College of Physicians and Surgeons.

(See a Problem?)

Anissa Abi-Dargham's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. (1996) (1271)
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. (2000) (1039)
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. (1998) (805)
The nature of dopamine dysfunction in schizophrenia and what this means for treatment. (2012) (797)
Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia (2002) (732)
Increased dopamine transmission in schizophrenia: relationship to illness phases (1999) (711)
Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum (2003) (568)
Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. (2010) (499)
Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies (1999) (427)
Alcohol Dependence Is Associated with Blunted Dopamine Transmission in the Ventral Striatum (2005) (425)
Glutamate, Dopamine, and Schizophrenia (2003) (409)
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia (2000) (398)
Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. (1993) (370)
Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. (1998) (358)
Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms (2019) (348)
Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release (1995) (347)
Do we still believe in the dopamine hypothesis? New data bring new evidence. (2004) (342)
Neurobiology of dopamine in schizophrenia. (2007) (326)
Low dopamine D(2) receptor binding potential in social phobia. (2000) (319)
Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. (2003) (317)
Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. (2005) (307)
Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. (2015) (304)
Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. (2012) (284)
Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia (2003) (277)
Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans (1997) (275)
Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. (2005) (247)
Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. (1993) (239)
Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions (2000) (231)
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans (1999) (228)
Dopamine hypothesis of schizophrenia: Making sense of it all (2007) (213)
The role of serotonin in the pathophysiology and treatment of schizophrenia. (1997) (212)
Pathway-Specific Dopamine Abnormalities in Schizophrenia (2017) (204)
COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET (2008) (202)
The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans (2001) (195)
Sex Differences in Striatal Dopamine Release in Young Adults After Oral Alcohol Challenge: A Positron Emission Tomography Imaging Study With [11C]Raclopride (2010) (195)
Baseline and Amphetamine-Stimulated Dopamine Activity Are Related in Drug-Naïve Schizophrenic Subjects (2009) (190)
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans (1998) (184)
Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions (2000) (184)
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery (2014) (182)
Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies (2005) (181)
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. (2007) (173)
Cognitive and brain function in schizotypal personality disorder (2002) (162)
Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. (2004) (159)
SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. (1994) (158)
Measurement of Striatal and Extrastriatal Dopamine D1 Receptor Binding Potential With [11C]NNC 112 in Humans: Validation and Reproducibility (2000) (154)
Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. (2005) (153)
Altered prefrontal dopaminergic function in chronic recreational ketamine users. (2005) (152)
GABA level, gamma oscillation, and working memory performance in schizophrenia (2014) (151)
In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (–)‐N‐[11C]propyl‐norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]‐raclopride (2004) (151)
In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. (2000) (150)
Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT (2000) (149)
Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings (2014) (147)
The search for imaging biomarkers in psychiatric disorders (2016) (136)
Cannabis-associated psychosis: Neural substrate and clinical impact (2017) (135)
SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. (1996) (130)
Deficits in Predictive Coding Underlie Hallucinations in Schizophrenia (2014) (130)
Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol: A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans (2001) (126)
Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine (2009) (126)
Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride (2008) (125)
Increased prefrontal cortical D1 receptors in drug naïve patients with schizophrenia: a PET study with [11C]NNC112 (2012) (122)
Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide (2004) (121)
Striatal and extrastriatal dopamine release measured with PET and [18F] fallypride (2010) (116)
Dopamine Release in Chronic Cannabis Users: A [11C]Raclopride Positron Emission Tomography Study (2012) (106)
PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756 (1998) (106)
SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: II. Equilibrium Analysis of Constant Infusion Experiments and Correlation with in vitro Parameters (1994) (105)
A Perceptual Inference Mechanism for Hallucinations Linked to Striatal Dopamine (2018) (101)
Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies (2014) (99)
In Vivo DA D1 Receptor Selectivity of NNC 112 and SCH 23390 (2007) (98)
Deficits in striatal dopamine release in cannabis dependence (2016) (97)
Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. (1994) (96)
Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain (2019) (95)
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO (2016) (92)
Dopamine Depletion and In Vivo Binding of PET D1 Receptor Radioligands: Implications for Imaging Studies in Schizophrenia (2003) (92)
Striatal Dopamine Release in Schizophrenia Comorbid with Substance Dependence (2012) (91)
Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [11C]McN 5652 (2003) (91)
Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings (2008) (90)
Coadministration of fluvoxamine increases serum concentrations of haloperidol. (1994) (90)
Alterations of serotonin transmission in schizophrenia. (2007) (89)
Stability of [123I]IBZM SPECT measurement of amphetamine‐induced striatal dopamine release in humans (1999) (87)
Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. (2006) (85)
Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder (2009) (84)
Mechanisms of Working Memory Impairment in Schizophrenia (2016) (84)
Increased Serotonin 2A Receptor Availability in the Orbitofrontal Cortex of Physically Aggressive Personality Disordered Patients (2010) (83)
Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder (2015) (82)
Impact of D2 Receptor Internalization on Binding Affinity of Neuroimaging Radiotracers (2010) (80)
The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia (2006) (79)
Effects of reduced endogenous 5‐HT on the in vivo binding of the serotonin transporter radioligand 11C‐DASB in healthy humans (2005) (79)
Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652 (2002) (77)
Schizophrenia: overview and dopamine dysfunction. (2014) (69)
Presynaptic regulation of dopamine transmission in schizophrenia. (2011) (68)
Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naı̈ve healthy volunteers: results from a large cohort (2003) (67)
Striatal and Extrastriatal Dopamine D2/D3 Receptors in Schizophrenia Evaluated With [18F]fallypride Positron Emission Tomography (2010) (67)
Imaging Changes in Glutamate Transmission In Vivo with the Metabotropic Glutamate Receptor 5 Tracer [11C] ABP688 and N-Acetylcysteine Challenge (2011) (64)
Prediction of panic response to a respiratory stimulant by reduced orbitofrontal cerebral blood flow in panic disorder. (2005) (64)
Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil. (1995) (63)
Striatal dopamine in bulimia nervosa: a PET imaging study. (2012) (63)
Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635 (2006) (63)
The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. (2012) (61)
[11C]NNC 112 Selectivity for Dopamine D1 and Serotonin 5-HT2A Receptors: A PET Study in Healthy Human Subjects (2007) (60)
Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction? (2012) (60)
Sustained Recreational Use of Ecstasy Is Associated with Altered Pre and Postsynaptic Markers of Serotonin Transmission in Neocortical Areas: A PET Study with [11C]DASB and [11C]MDL 100907 (2012) (59)
Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us? (2003) (59)
No Evidence of Altered In Vivo Benzodiazepine Receptor Binding in Schizophrenia (1999) (57)
Pharmacological and Regional Characterization of [3H]LY278584 Binding Sites in Human Brain (1993) (57)
Serotonin Transporter Availability in Patients with Schizophrenia: A Positron Emission Tomography Imaging Study with [11C]DASB (2005) (57)
Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance (2020) (54)
Imaging human reward processing with positron emission tomography and functional magnetic resonance imaging (2012) (52)
Dopamine D1 signaling organizes network dynamics underlying working memory (2016) (52)
Dopamine-Related Disruption of Functional Topography of Striatal Connections in Unmedicated Patients With Schizophrenia. (2016) (52)
Presynaptic Dopamine in Schizophrenia (2011) (51)
Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications (2003) (49)
Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. (1999) (48)
An integrative framework for perceptual disturbances in psychosis (2019) (48)
Cannabis Abusers Show Hypofrontality and Blunted Brain Responses to a Stimulant Challenge in Females but not in Males (2016) (47)
[123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia (1999) (46)
A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia (2016) (45)
Imaging the neurochemistry of alcohol and substance abuse. (2007) (45)
Dynamic shifts in brain network activation during supracapacity working memory task performance (2015) (44)
Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET. (2006) (43)
Binding of serotonergic ligands to brain membranes of alcohol-preferring AA and alcohol-avoiding ANA rats. (1992) (43)
In Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [11C]-(+)-PHNO (2010) (39)
Serotonin 2A Receptors in Obsessive-Compulsive Disorder: A Positron Emission Tomography Study with [11C]MDL 100907 (2011) (39)
Motivational Context Modulates Prediction Error Response in Schizophrenia. (2016) (37)
Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine (2005) (37)
Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. (2020) (37)
Preclinical evaluation of [123I]R93274 as a SPECT radiotracer for imaging 5-HT2A receptors. (1997) (36)
Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [123I]iomazenil. (1993) (35)
Shall we really say goodbye to first rank symptoms? (2016) (35)
Extended characterisation of the serotonin 2A (5-HT2A) receptor-selective PET radiotracer 11C-MDL100907 in humans: Quantitative analysis, test–retest reproducibility, and vulnerability to endogenous 5-HT tone (2012) (34)
The 5-HT2A receptor and serotonin transporter in Asperger's Disorder: A PET study with [11C]MDL 100907 and [11C]DASB (2011) (33)
Dynamic Connectivity between Brain Networks Supports Working Memory: Relationships to Dopamine Release and Schizophrenia (2016) (32)
Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses (2019) (31)
Schizophrenia is associated with increased synaptic dopamine in associative rather than limbic regions of the striatum: Implications for mechanisms of action of antipsychotic drugs (2006) (31)
Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [11C]NNC112 (2014) (31)
Positron Emission Tomography Imaging of the Serotonin Transporter and 5-HT1A Receptor in Alcohol Dependence (2009) (30)
Characterization of in vivo Pharmacokinetic Properties of the Dopamine D1 Receptor Agonist DAR-0100A in Nonhuman Primates Using PET with [11C] NNC112 and [11C] Raclopride (2011) (28)
Dynorphin and the Kappa Opioid Receptor’s Role in the Symptomatology of Schizophrenia: A Review of the Evidence (2019) (28)
Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: A positron emission tomography study in Papio anubis (2011) (27)
Recent evidence for dopamine abnormalities in schizophrenia (2002) (26)
Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. (2003) (26)
Aberrant Temporal Connectivity in Persons at Clinical High Risk for Psychosis. (2017) (25)
A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia (2019) (25)
Serotonin 5-HT3 receptors in schizophrenia: a postmortem study of the amygdala (1993) (24)
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms (2002) (24)
Initial characterization of a PDE10A selective positron emission tomography tracer [11C]AMG 7980 in non-human primates. (2014) (24)
Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: preliminary analyses. (2000) (23)
Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study (2018) (23)
Serotonin transporter availability in impulsive aggressive personality disordered patients: a PET study with [11C]DASB. (2014) (22)
Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [11C]-(+)-PHNO (2015) (21)
In vivo binding of the dopamine-1 receptor PET tracers [11C]NNC112 and [11C]SCH23390: a comparison study in individuals with schizophrenia (2013) (21)
Distinct Relationships Between Visual and Auditory Perceptual Abnormalities and Conversion to Psychosis in a Clinical High-Risk Population (2017) (20)
An evaluation of the brain distribution of [11C]GSK1034702, a muscarinic-1 (M1) positive allosteric modulator in the living human brain using positron emission tomography (2014) (20)
Safety of Radial Arterial Catheterization in PET Research Subjects (2009) (19)
Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder (2020) (19)
Effects of L-DOPA Monotherapy on Psychomotor Speed and [11C]Raclopride Binding in High-Risk Older Adults With Depression (2019) (18)
Enhanced Striatal Dopamine Release to Expectation of Alcohol: A Potential Risk Factor for Alcohol Use Disorder. (2018) (18)
PET imaging of dopamine-D2 receptor internalization in schizophrenia (2017) (18)
From “bedside” to “bench” and back: A translational approach to studying dopamine dysfunction in schizophrenia (2020) (17)
Neurochemical imaging in schizophrenia. (2010) (17)
Molecular imaging in alcohol dependence. (2014) (17)
PET Studies of Binding Competition Between Endogenous Dopamine and the D 1 (1999) (17)
Integrating the neurobiology of schizophrenia (2007) (16)
Schizophrenia: the role of dopamine and glutamate. (2014) (16)
Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study (2019) (16)
Cortical inhibition in alcohol dependence. (2000) (16)
Shape distortion of the corpus callosum of monozygotic twins discordant for schizophrenia (1990) (16)
Evidence for Dopamine Abnormalities in the Substantia Nigra in Cocaine Addiction Revealed by Neuromelanin-Sensitive MRI. (2020) (15)
Dimerization of phenols and naphthols using an aqueous sodium hypochlorite (2010) (15)
Is it Pre- or Postsynaptic? Imaging Striatal Dopamine Excess in Schizophrenia (2018) (15)
Integrating acquired preparedness and dual process models of risk for heavy drinking and related problems. (2015) (14)
Neural Dysfunction in Cognitive Control Circuits in Persons at Clinical High-Risk for Psychosis (2016) (13)
Recent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders. (2017) (13)
18. Evidence against progression of in vivo anatomical abnormalities in schizophrenia (1991) (13)
Optimizing pharmacotherapy to maximize outcome in schizophrenia. (2005) (13)
Imaging dopamine transmission parameters in cannabis dependence (2014) (12)
Two Hypotheses on the High Incidence of Dementia in Psychotic Disorders. (2021) (12)
How have developments in molecular imaging techniques furthered schizophrenia research? (2009) (12)
Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO (2019) (11)
Dopamine dysfunction in schizophrenia (2014) (10)
Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone (2011) (10)
Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials (2020) (10)
The striatum and dopamine: a crossroad of risk for schizophrenia. (2014) (10)
Modulating ketamine-induced thought disorder with lorazepam and haloperidol in humans (1995) (10)
Dopamine in the history of the schizophrenic brain: recent contributions of brain-imaging studies (2000) (9)
Differential reinforcement learning responses to positive and negative information in unmedicated individuals with depression (2021) (8)
Serotonin Receptors as Targets of Antipsychotic Medications (2000) (8)
A Dual Hit Model for Dopamine in Schizophrenia (2017) (8)
Human biodistribution and dosimetry of iodine-123-fluoroalkyl analogs of β-CIT (1997) (8)
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. (2021) (7)
Cross‐Scanner Harmonization of Neuromelanin‐Sensitive MRI for Multisite Studies (2021) (7)
SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia (1996) (6)
Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study (2020) (6)
PET imaging of dopamine-D2 receptor internalization in schizophrenia. (2017) (6)
Emerging Treatments in Schizophrenia. (2022) (6)
SEROTONIN AND SCHIZOPHRENIA : A REVIEW (1996) (6)
Alterations in cortical and extra-striatal sub-cortical dopamine function in schizophrenia: a systematic review and meta-analysis of imaging studies (2013) (6)
Tryptophan depletion paradigm: Implications for schizophrenia (1994) (6)
Differentiating nmda dysregulation in schizophrenia and alcoholism using ketamine (1995) (6)
Benzodiazepine Receptor Antagonists (1997) (6)
Pharmacological selectivity of the in vivo binding of [11C]NNC 112 and [11C]SCH 23390 in the cortex: A PET study in baboons (2006) (5)
Is It in Our Genes: Oxytocin, Dopamine, Stress, and Sex (2012) (5)
Integrating the neurobiology of schizophrenia. Preface. (2007) (5)
SPECTImagingof StriatalDopamineRelease after Amphetamine Challenge (1995) (4)
Impact of dopamine D2 receptor internalization on binding parameters of D2 PET radiotracers (2008) (4)
Amphetamine-induced striatal dopamine release in schizotypal personality disorder (2020) (4)
Human biodistribution and dosimetry of iodine-123-fluoroalkyl analogs of beta-CIT. (1997) (4)
Imaging Receptor Occupancy by Endogenous Transmitters in Humans (1998) (4)
Evidence from brain imaging studies for dopaminergic alterations in schizophrenia (2003) (4)
PET studies of frontal lobe function during cognition (1991) (4)
The roles of the dorsolateral prefrontal cortex and hippocampus in working memory and schizophrenia (1994) (3)
Effect of antipsychotic treatment on cortical D1 receptors (2010) (3)
Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient. (1994) (3)
208. Increased striatal dopamine release in drug free schizophrenic subjects (1996) (3)
Studying schizophrenia in the post-genomic era: perspectives from the 2016 summer Banbury Workshop at Cold Spring Harbor Laboratory (2017) (3)
Comparison of Kinetic Modeling Methods for the In Vivo Quantification of 5-HT1A Receptors Using WAY 100635 (2001) (3)
In Vivo Imaging of Dopamine Receptors (2010) (3)
Ibotenic acid or ablation lesions of the frontal cortex do not alter the density or the affinity of D1 and D2 receptors in the corpus striatum or nucleus accumbens (1991) (3)
Spect imaging of the benzodiazepine receptor in schizophrenics and healthy subjects (1995) (3)
In vivo binding of antipsychotics to D3 and D2 receptors: A PET study in baboons with [11C]-(+)-PHNO (2010) (3)
Dopamine Imbalances in the Schizophrenic Brain (2003) (3)
Molecular Imaging in Psychiatric Disorders (2003) (3)
507 In vivo evaluation of dopamine synaptic funcflon in untreated schizophrenic patients (1997) (2)
Parametric Variation in Working Memory Demand in Patients With Schizophrenia: A Behavioral and Neuroimaging Pilot Study (2010) (2)
194. Neuromelanin-sensitive Mri as an Early Indicator of Dopamine Dysfunction in Individuals at Risk for Psychosis (2017) (2)
Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research (2016) (2)
Imaging dopamine transmission in cannabis dependence (2010) (2)
Biological Psychiatry and Biological Psychiatry: Cognitive Neuroscience and Neuroimaging Adopt Neuroscience-Based Nomenclature. (2016) (2)
Biological Psychiatry and Biological Psychiatry: Cognitive Neuroscience and Neuroimaging Adopt Neuroscience-Based Nomenclature (2016) (2)
Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PETstudy (2014) (2)
Publisher Correction: An integrative framework for perceptual disturbances in psychosis (2020) (2)
Ketamine impairs learning, but not procedural expression, on the wisconsin card sorting test (1995) (2)
Neuroanatomical predictors of L-DOPA response in older adults with psychomotor slowing and depression: A pilot study. (2020) (2)
PET imaging of D1 receptors in striatal subdivisions in schizophrenia (2009) (1)
SPECT Imaging of Resting Dopamine Synaptic Release in the Striatum of Untreated Schizophrenic Patients (1998) (1)
Amphetamine-induced striatal dopamine release in major depressive disorder (2010) (1)
Chapter 24 Antipsychotic-Induced Changes in Striatal D2 Receptors in Schizophrenia: In Vivo Evidence from Dopamine Depletion Studies (2012) (1)
Dopamine and Schizophrenia (2011) (1)
Blunted striatal dopamine release in cannabis dependence (2015) (1)
Department of Psychiatry and Behavioral Sciences Grand Rounds (2020) (1)
177.4 Dopamine Glutamate Interactions in Patients With Schizophrenia (2017) (1)
The Neurochemistry of Schizophrenia: A Focus on Dopamine and Glutamate (2011) (1)
Deep rTMS of the insula and prefrontal cortex in smokers with schizophrenia: Proof-of-concept study (2022) (1)
A regression method to estimate bindng potential when all data are not available from the moment of injection (2015) (1)
Cortical Dopamine in Schizophrenia (2009) (1)
334. Subcortical dopaminergic activity in schizotypal personality disorder (2000) (1)
494 Spect measurement of human striatal synaptic dopamine concentration with [123I]IBZM (1997) (1)
[18F]Fallypride PET assessment of D2/D3 receptor binding in schizophrenia (2008) (1)
Synaptic plasticity as a therapeutic target to modulate circuits in psychiatric disorders (2022) (1)
253. Utilizing a Behavioral Assay of Reward Learning to Predict Clinical Response to a Dopamine Agonist in Individuals With Depression (2018) (1)
Imaging drug action in schizophrenia: research update (2003) (1)
Spect imaging of the benzodiazepine receptor in humans using [123I]iomazenil (1993) (1)
Imaging the "GABA shift" in schizophrenia. (2015) (1)
Reproducibility of Radioligand Measurements of Pharmacologically Induced Striatal Dopamine Release in Humans (2001) (1)
Activation in the dorsolateral prefrontal cortex during working memory is associated with dopamine release capacity (2014) (1)
In vivo binding of the dopamine-1 receptor PET tracers [11C]NNC112 and [11C]SCH23390: a comparison study in individuals with schizophrenia (2013) (1)
DOPAMINE D3 RECEPTOR OCCUPANCY AND D3 RECEPTOR-MEDIATED ACTIONS OF CARIPRAZINE, A DOPAMINE D3/D2 RECEPTOR PARTIAL AGONIST ANTIPSYCHOTIC CANDIDATE (2014) (1)
Differential occupancy of 5HT-1A autoreceptors and post-synaptic receptors by pindolol in humans measured with PET and [ 11C-carbonyl] WAY 100635 (2000) (1)
Vulnerability of [18F]fallypride in vivo binding in striatal and extrastriatal regions following a D-amphetamine challenge in baboons: Single bolus and bolus plus constant infusion studies (2003) (1)
Dimerization of Phenols and Naphthols Using an Aqueous Sodium Hypochlorite. (2010) (0)
Neurochemistry of obsessive–compulsive disorder: A combined PET and MRS study (2010) (0)
The multifaceted aspects of the dopaminergic dysfunction in schizophrenia S1: Uncovering the circuitry of depression and how it guides the development of novel treatment strategies (2016) (0)
D2 AND DA RELEASE IN COMORBID DEPENDENCE AND SCHIZOPHRENIA (2012) (0)
New probes for imaging dopamine transmission in at risk subjects for alcoholism (2008) (0)
JAMA Psychiatry Peer Reviewer List. (2017) (0)
Multitask Learning Based Three‐Dimensional Striatal Segmentation of MRI: fMRI and PET Objective Assessments (2021) (0)
Combined spect and MRS study of subcortical dopamine dysregulation in schizophrenia (2003) (0)
Cortical D1 across COMT genotypes (2006) (0)
Imaging Dopamine Alterations in Cannabis Dependence (2016) (0)
Reproducibility of SPECT Measurement of Striatal Amphetamine-Induced Dopamine Release in Healthy Subjects (1998) (0)
Amphetamine challenge with [18F]fallypride: Striatal and extrastriatal measurements in healthy human volunteers (2008) (0)
PET imaging of the serotonin transporter and 5HT1A receptor in alcohol dependence (2009) (0)
326. GABA-serotonin interactions in healthy subjects: Implications for psychosis (1996) (0)
S236. Neuromelanin-Sensitive MRI: A Novel, Non-Invasive Proxy Measure of Dopamine Function in Neuropsychiatric Illness (2018) (0)
A Retrospective on PET and the Amphetamine Paradigm: Validation and Paradoxes (2014) (0)
103. Dopaminergic Decline, Psychomotor Slowing, and Late Life Depression (2019) (0)
IS THE ASSOCIATIVE STRIATUM A LOCUS OF VULNERABILITY FOR TRANSITION TO PSYCHOSIS? (2014) (0)
Combined PET and MRS study of neurochemistry of obsessive-compulsive disorder (2010) (0)
F210. Preliminary MRI Evidence of Abnormal Neuromelanin Accumulation in the Substantia Nigra in Cocaine-Use Disorder (2019) (0)
GABA AND GLUTAMATE-GLUTAMINE LEVELS IN THE FRONTAL CORTEX IN SCHIZOPHRENIA: A MAGNETIC RESONANCE SPECTROSCOPY STUDY (2010) (0)
of imaging studies function in schizophrenia: systematic review and meta-analysis Alterations in cortical and extrastriatal subcortical dopamine (2014) (0)
Illness Phase as a Key Assessment and Intervention Window for Psychosis (2022) (0)
In vivo pharmacological evaluation of the 5HT-1B radioligand [11C]P943 in nonhuman primates using PET (2008) (0)
Radioligands for Imaging of the CNS Acetylcholinergic System (2021) (0)
251. Dopamine Release in Treatment-Naïve Major Depressive Disorder: A [11C]-(+)-PHNO Positron Emission Tomography Study (2018) (0)
Multi-Task Learning based 3-Dimensional Striatal Segmentation of MRI – a Multi-modal Objective Assessment (2020) (0)
PLENARYSESSION II S 40 PREFRONTALDOPAMINE TRANSMISSION IN SCHIZOPHRENIA : ISD 1 RECEPTORARELEVANTBIOMARKER ? (2005) (0)
International Scientific Advisory Committee (2012) (0)
Cross-Scanner Harmonization of Neuromelanin-Sensitive MRI for Multi-Site Studies (2021) (0)
3.3 DISTURBANCES IN NEURAL OSCILLATIONS, GLUTAMATE, AND GABA: EFFECTS OF KETAMINE AND COMPARISON TO SCHIZOPHRENIA (2018) (0)
Constrained methods for kinetic modeling of amphetamine effect in human cortex with [11C]FLB457 (2014) (0)
Chapter 27 Antipsychotic-Induced Changes in Striatal D2 Receptors in Schizophrenia: In Vivo Evidence from Dopamine Depletion Studies (2013) (0)
Measurement of neurotransmitters with positron emission tomography (2003) (0)
NPP: Our Designs for the Future (2017) (0)
Dopamine transmission in comorbid schizophrenia and substance dependence (2010) (0)
Serotonin transporter availability in physically aggressive personality disordered patients: associations with trait and state aggression, and response to fluoxetine (2023) (0)
Reviewers for The American Journal of Psychiatry. (2017) (0)
Publisher Correction: An integrative framework for perceptual disturbances in psychosis (2020) (0)
Computational Approaches to Improving Treatment Precision for Anhedonia (2020) (0)
Imaging human reward processing with positron emission tomography and functional magnetic resonance imaging (2011) (0)
Imaging of Genetic Variation Impacting Dopamine Transmission Parameters (2016) (0)
Dose occupancy relationship for a D1 agonist using [11C] NNC 112 in primates (2009) (0)
THE ABNORMAL LIFE OF THE D2 RECEPTOR IN SCHIZOPHRENIA (2012) (0)
Correlation between PET and microdialysis measurements of amphetamine induced DA release in striatal and extrastriatal brain regions in baboons (2007) (0)
252. Major Depressive Disorder is Associated With Blunted Learning Signals in Medial Prefrontal Cortex and Putamen When Seeking Monetary Reward (2018) (0)
Introduction (2014) (0)
Deep rTMS of the insula disrupts cigarette self-administration and modulates insula-centric brain function in smokers with schizophrenia (2021) (0)
27.1 TRANSLATIONAL EVIDENCE OF DOPAMINE-RELATED ALTERATIONS OF BASAL GANGLIA AND THALAMO-CORTICAL NEUROCIRCUITRY IN SCHIZOPHRENIA: A FULL CLINIC-TO-BENCH-TO-CLINIC BACK-TRANSLATION (2018) (0)
Acknowledgment of Reviewers 2018 (2018) (0)
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia measured with [18F]fallypride PET (2007) (0)
Speaker 1: Gitte Moos Knudsen, Denmark (2016) (0)
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO (2016) (0)
58.4 Studies of Comorbid Schizophrenia and Addiction Reveal a State of Supersensitivity of the D2 Receptor (2017) (0)
27. THE ROLE OF DOPAMINE IN SHAPING CIRCUITRY RELATED TO SCHIZOPHRENIA AND ADDICTION (2018) (0)
Imaging reward function in healthy volunteers with PET and fMRI (2009) (0)
Retraction notice to "Neuroanatomical predictors of L-DOPA response in older adults with psychomotor slowing and depression: A pilot study" [J. Affect. Disord. 265 (2020) 439-444]. (2023) (0)
ABNORMALITIES OF FRONTOSTRIATAL CIRCUITS IN THE PSYCHOSIS PRODROME (2014) (0)
CINP 2005 Regional Meeting, 20-22 April 2005 (2005) (0)
Medial Prefrontal Cortex Dysfunction Mediates Working Memory Deficits in Patients with Schizophrenia (2022) (0)
LINKING DOPAMINE DYSREGULATION TO SYMPTOMS AND CLINICAL PHASE BRAIN IMAGING STUDIES (2010) (0)
Ketamine effects reduced by lorazepam in healthy humans (1993) (0)
Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [11C]NNC112 (2014) (0)
An integrative framework for perceptual disturbances in psychosis (2019) (0)
D2/D3 receptor binding in striatal and extrastriatal regions in schizophrenia measured with [18F]fallypride PET (2008) (0)
Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics (2021) (0)
Reviewers for The American Journal of Psychiatry. (2015) (0)
GABA AND GLUTAMATE AS POTENTIAL THERAPEUTIC TARGETS IN SCHIZOPHRENIA (2014) (0)
Molecular Brain Imaging Research in Mental Illness (2011) (0)
Author ’ s Accepted Manuscript Aberrant Temporal Connectivity in Persons at Clinical High Risk for PsychosisFunctional Dysconnectivity in the Clinical High Risk (2017) (0)
Imaging alcohol-induced dopamine release in the human striatum (2008) (0)
118. The Challenges of Testing D1 Agonists in Schizophrenia (2019) (0)
Ubiquitous Dopamine Deficit Hypotheses in Cocaine Use Disorder Lack Support: Response to Leyton. (2021) (0)
S40 PREFRONTAL DOPAMINE TRANSMISSION IN SCHIZOPHRENIA: IS D1 RECEPTOR A RELEVANT BIOMARKER? (2005) (0)
Dopamine in schizophrenia: where does it stand in the cascade of pathological events? (2016) (0)
Reproducibility and sensitivity to pharmacological challenge of [11C]-ABP688 in non-human primate brain (2010) (0)
Speaker: Anissa Abi-Dargham, USA (2016) (0)
Letter to the Editor: A Novel Therapeutic for Opioid Use Disorder Targeting the Cholinergic System. (2019) (0)
43.4 THE ROLE OF MOLECULAR IMAGING IN GUIDING DRUG DEVELOPMENT (2018) (0)
The 5-HT2A receptor and serotonin transporter in ecstasy users evaluated with [11C]MDL 100907 and [11C]DASB (2011) (0)
The 5HT-2A receptor and 5HT transporter in Asperger's disorder: A PET study with [11C]MDL and [11C]DASB (2010) (0)

This paper list is powered by the following services:

Other Resources About Anissa Abi-Dargham

en.wikipedia.org

What Schools Are Affiliated With Anissa Abi-Dargham?

Anissa Abi-Dargham is affiliated with the following schools: